Value Adjusted for Debt and Cash: fortebiorx.com (FBRX)

Brandmark of Forte Biosciences Inc (FBRX)

This chart of the enterprise value history for Forte Biosciences, Inc. (FBRX) on GURU.Markets is 1436.04. The financial stability of the dermatology developer relies exclusively on attracting research investments, while the California office minimizes downtime risks by utilizing third-party outsourcing for drug synthesis. Growth prospects depend on the trials of the FB-102 drug and its potential in the therapy of autoimmune skin pathologies.

fortebiorx.com (FBRX) - Total Company Value from 11/23/2025 to 09/06/2026

Forte Biosciences, Inc. (FBRX) - metric breakdowns and financial figures

- stock price and consensus target price:
Price Chart Forte Biosciences Inc.|FBRX - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Forte Biosciences|FBRX - Real Price to Acquire Entire Company
- book capitalization information:
Equity per Share Forte Biosciences|FBRX - Company Book Value|Market Capitalization to Net Assets fortebiorx.com|FBRX - Company Total Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Forte Biosciences, Inc.|FBRX - Long-Term Debt to Capital|Short-Term Debt to Capital fortebiorx.com|FBRX - Company Debts|Debt to Net Assets Ratio Forte Biosciences|FBRX - Company Long-Term Debt|Company Current Liabilities Forte Biosciences|Quick Ratio fortebiorx.com
- earnings and valuation multiples indicators:
FBRX - Net Income
Analysis of all company metrics:Forte Biosciences Inc.
Brand item of Forte Biosciences, Inc.

This metric determines the investment attractiveness of Forte Biosciences, Inc. (FBRX) by summing market capitalization with net debt to identify the actual cost of business acquisition. By analyzing the enterprise value, an investor can see the capitalization of intellectual assets, where a high valuation is justified by exclusive patents for dermatological drugs and stringent barriers to entry within the FDA sector.

Competitors of Forte Biosciences, Inc. (FBRX)

Krystal Biotech Inc - Total Company Value|APGE - Total Company Value|Value Adjusted for Debt and Cash ARQT (Arcutis Corp)|VCEL (Vericel Corporation) - Real Price to Acquire Entire Company|Business Value ORKA|Total Company Value Sanara MedTech, Inc.|DBV Technologies SA - Full Business Value|Enterprise Value SLSN|DERM (journeymedicalcorp.com) - Value Adjusted for Debt and Cash|Enterprise Value EMPG (Empro Group Inc)|Enterprise Value sol-gel.com SLGL|AXIL - Total Company Value|Value Adjusted for Debt and Cash MDCX (Medicus Pharma Ltd)|verrica.com (VRCA) - Total Company Value|Real Price to Acquire Entire Company Hoth Therapeutics|BFRI (Biofrontera, Inc.) - Enterprise Value|Enterprise Value VYNE Therapeutics Inc|Real Price to Acquire Entire Company SNOA (Sonoma Pharmaceuticals)|QNRX (quoinpharma.com) - Value Adjusted for Debt and Cash|Total Company Value Azitra Corp AZTR|Company Buyout Price Dermata Corp (DRMA)|ELAB - Total Company Value|RVNC - Enterprise Value